- Novel Coronavirus
-
Drug Discovery Services
- Antiviral Drug Discovery
- Complement Therapy
- SARS-CoV-2 Aptamers
- Antisense Oligonucleotides
- Protease Inhibitors
- Inhibitor of Host Cell Protease
- Abelson Kinase Inhibitors
- RNA Synthesis Inhibitors
- Nucleoside Analogue
- Neuraminidase Inhibitors
- Neutralizing Antibody
- Antiviral Peptide
- Broad-spectrum Antiviral Drug
- Anti-Inflammatory Drugs
- High-Throughput Screening
- Vaccine Discovery
- Evaluation Platforms for SARS-CoV-2 Drugs
- Antiviral Drug Discovery
- IVD Immunoassays
- Products
- Resources
- About Us
SARS-CoV-2 Spike Neutralizing Antibody (Human IgM) (CAT#: VAb-Wyb101)
- Product Overview
- The product serotype human IgM recognizes SARS-CoV-2 S/S-RBD Protein and block ACE-2 receptor binding.
- Target
- SARS-CoV-2
- Source
- Cultured in vitro under conditions free from animal derived components.
- Clonality
- MAb
- Specificity
- Antibody recognizes SARS-CoV-2 S/S-RBD Protein
- Type
- Antibody
- Form
- Liquid
- Buffer Solution
- PBS, pH 7.4.
- Applications
- Used for ELISA.
- Storage
- Store at -20°C.
- Introduction
- The 2019 novel coronavirus, or "SARS-CoV-2", was discovered because of Wuhan virus pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family, together with SARS coronavirus in 2003 and MERS coronavirus in 2012. The alignment between SARS-CoV-2 and 2003 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. The coronavirus genome encodes a spike protein, an envelope protein, a membrane protein, and a nucleoprotein. Among them, spike protein is the most important surface membrane protein of coronavirus.
- Alternative Names
- 2019 novel coronavirus; SARS-CoV-2; Coronaviridae
Online Inquiry
For Research Use Only. We do not provide direct services or products for patients.
For Research Use Only. We do not provide direct services or products for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.